Literature DB >> 15479859

Polymorphisms in the osteopontin promoter affect its transcriptional activity.

Francesca Giacopelli1, Renato Marciano, Angela Pistorio, Paolo Catarsi, Silvana Canini, Gerard Karsenty, Roberto Ravazzolo.   

Abstract

Understanding the molecular mechanisms that underlie regulation of transcription of the human osteopontin encoding gene (OPN) may help to clarify several processes, such as fibrotic evolution of organ damage, tumorigenesis and metastasis, and immune response, in which OPN overexpression is observed. With the aim to evaluate variants with functional effect on transcription, we have analyzed the promoter region and focused our investigation on three common variants present in the first 500 bp upstream of the transcription start site. Transfection of constructs carrying the four most frequent haplotypes relative to variants at -66, -156, and -443 fused to the luciferase reporter gene in a panel of different cell lines showed that one haplotype conferred a significantly reduced level of reporter gene expression in all tested cell lines. We describe that the -66 polymorphism modifies the binding affinity for the SP1/SP3 transcription factors, the -156 polymorphism is included in a yet uncharacterized RUNX2 binding site, and the -443 polymorphism causes differential binding of an unknown factor. The finding of differential effects of various combination of variants in haplotypes may contribute to explain data of association studies reported in several already published articles. Future association studies using haplotypes instead of single OPN variants will allow to achieve more accurate results referable to differential expression of OPN in several common diseases, in which OPN is considered a candidate susceptibility gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479859     DOI: 10.1152/physiolgenomics.00138.2004

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  53 in total

Review 1.  Linking variants from genome-wide association analysis to function via transcriptional network analysis.

Authors:  Benjamin Keller; Sebastian Martini; John Sedor; Matthias Kretzler
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

2.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

3.  A polymorphic variant inside the osteopontin gene shows association with disease course in oligoarticular juvenile idiopathic arthritis.

Authors:  R Marciano; F Giacopelli; M T Divizia; M Gattorno; E Felici; A Pistorio; A Martini; R Ravazzolo; P Picco
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

4.  Alterations in osteopontin modify muscle size in females in both humans and mice.

Authors:  Eric P Hoffman; Heather Gordish-Dressman; Virginia D McLane; Joseph M Devaney; Paul D Thompson; Paul Visich; Paul M Gordon; Linda S Pescatello; Robert F Zoeller; Niall M Moyna; Theodore J Angelopoulos; Elena Pegoraro; Gregory A Cox; Priscilla M Clarkson
Journal:  Med Sci Sports Exerc       Date:  2013-06       Impact factor: 5.411

5.  Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study.

Authors:  Brent C Taylor; Pamela J Schreiner; Terence M Doherty; Myriam Fornage; J Jeffrey Carr; Steve Sidney
Journal:  Hum Genet       Date:  2005-03-03       Impact factor: 4.132

6.  Secreted phosphoprotein 1 is a determinant of lung function development in mice.

Authors:  Koustav Ganguly; Timothy M Martin; Vincent J Concel; Swapna Upadhyay; Kiflai Bein; Kelly A Brant; Leema George; Ankita Mitra; Tania A Thimraj; James P Fabisiak; Louis J Vuga; Cheryl Fattman; Naftali Kaminski; Holger Schulz; George D Leikauf
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

Review 7.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 8.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

Review 9.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

10.  Dual effect of a single nucleotide polymorphism in the first intron of the porcine secreted phosphoprotein 1 gene: allele-specific binding of C/EBP beta and activation of aberrant splicing.

Authors:  Eduard Muráni; Siriluck Ponsuksili; Hans-Martin Seyfert; Xuanming Shi; Klaus Wimmers
Journal:  BMC Mol Biol       Date:  2009-10-21       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.